Global Pemetrexed Drug Market

Pemetrexed Drug Comprehensive Study by Application (Pleural mesothelioma, Lung Cancer, Colorectal Cancer, Stomach Cancer, Breast Cancer), Distribution Channel (Online, Offline), Strength (100 mg lyophilized powder/vial, 500 mg lyophilized powder/vial) Players and Region - Global Market Outlook to 2026

Pemetrexed Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pemetrexed Drug Market?

Pemetrexed drug is basically a drug that is used to treat cancer. It used in combination with other chemotherapy medications as a first treatment for a certain type of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. Pemetrexed is used to treat certain types of cancer such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. Pemetrexed drug is furthermore combined with alternative chemotherapy medication as a key treatment for malignant pleural mesothelioma (a sort of cancer that affects the within lining of the chest cavity) in people that can't be treated with surgery. Pemetrexed is a class of medicines called antifolate antineoplastic agents. It works by blocking the action of a certain element in the body that may help cancer cells grow.

The market study is being classified, by Application (Pleural mesothelioma, Lung Cancer, Colorectal Cancer, Stomach Cancer and Breast Cancer) and major geographies with country level break-up.

Eli Lilly and Company (United States), Fresenius KABI (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Dr Reddy’s Laboratories (India), Abbott Laboratories (United States), Cadila Healthcare Ltd (India), Accord Healthcare Inc. (United States), QILU Pharma Co Ltd. (China), Accure Labs Pvt. Ltd (India) and Pfizer Inc. (United States) are some of the key players profiled in the study.

Various generic players such as Eagle Pharmaceuticals Inc., and STADAPHARM GmbH have developed the generic pemetrexed. However, they are not able to enter the U.S. market due to patent of Eli Lilly and Company’s Alimta up to 2022. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Pemetrexed Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Pemetrexed Drug market by Type, Application and Region.

On the basis of geography, the market of Pemetrexed Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Use of Chemotherapy Drugs in Developing Countries
  • Increasing Cases of Cancer around the World


Restraints
  • Side Effects of Drug

Opportunities
  • Increasing Awareness among People
  • Rising Spending by People on Health

Challenges
  • High Cost of Chemo Therapy and Drug Development





Key Target Audience
Manufacturers Pemetrexed Drug, Distributors of Pemetrexed Drug, Healthcare Industry, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Application
  • Pleural mesothelioma
  • Lung Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Breast Cancer
By Distribution Channel
  • Online
  • Offline

By Strength
  • 100 mg lyophilized powder/vial
  • 500 mg lyophilized powder/vial

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Use of Chemotherapy Drugs in Developing Countries
      • 3.2.2. Increasing Cases of Cancer around the World
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Chemo Therapy and Drug Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pemetrexed Drug, by Application, Distribution Channel, Strength and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pemetrexed Drug (Value)
      • 5.2.1. Global Pemetrexed Drug by: Application (Value)
        • 5.2.1.1. Pleural mesothelioma
        • 5.2.1.2. Lung Cancer
        • 5.2.1.3. Colorectal Cancer
        • 5.2.1.4. Stomach Cancer
        • 5.2.1.5. Breast Cancer
      • 5.2.2. Global Pemetrexed Drug by: Distribution Channel (Value)
        • 5.2.2.1. Online
        • 5.2.2.2. Offline
      • 5.2.3. Global Pemetrexed Drug by: Strength (Value)
        • 5.2.3.1. 100 mg lyophilized powder/vial
        • 5.2.3.2. 500 mg lyophilized powder/vial
      • 5.2.4. Global Pemetrexed Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Pemetrexed Drug (Volume)
      • 5.3.1. Global Pemetrexed Drug by: Application (Volume)
        • 5.3.1.1. Pleural mesothelioma
        • 5.3.1.2. Lung Cancer
        • 5.3.1.3. Colorectal Cancer
        • 5.3.1.4. Stomach Cancer
        • 5.3.1.5. Breast Cancer
      • 5.3.2. Global Pemetrexed Drug by: Distribution Channel (Volume)
        • 5.3.2.1. Online
        • 5.3.2.2. Offline
      • 5.3.3. Global Pemetrexed Drug by: Strength (Volume)
        • 5.3.3.1. 100 mg lyophilized powder/vial
        • 5.3.3.2. 500 mg lyophilized powder/vial
      • 5.3.4. Global Pemetrexed Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Pemetrexed Drug (Price)
  • 6. Pemetrexed Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Fresenius KABI (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Dr Reddy’s Laboratories (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cadila Healthcare Ltd (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Accord Healthcare Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. QILU Pharma Co Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Accure Labs Pvt. Ltd (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pemetrexed Drug Sale, by Application, Distribution Channel, Strength and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pemetrexed Drug (Value)
      • 7.2.1. Global Pemetrexed Drug by: Application (Value)
        • 7.2.1.1. Pleural mesothelioma
        • 7.2.1.2. Lung Cancer
        • 7.2.1.3. Colorectal Cancer
        • 7.2.1.4. Stomach Cancer
        • 7.2.1.5. Breast Cancer
      • 7.2.2. Global Pemetrexed Drug by: Distribution Channel (Value)
        • 7.2.2.1. Online
        • 7.2.2.2. Offline
      • 7.2.3. Global Pemetrexed Drug by: Strength (Value)
        • 7.2.3.1. 100 mg lyophilized powder/vial
        • 7.2.3.2. 500 mg lyophilized powder/vial
      • 7.2.4. Global Pemetrexed Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Pemetrexed Drug (Volume)
      • 7.3.1. Global Pemetrexed Drug by: Application (Volume)
        • 7.3.1.1. Pleural mesothelioma
        • 7.3.1.2. Lung Cancer
        • 7.3.1.3. Colorectal Cancer
        • 7.3.1.4. Stomach Cancer
        • 7.3.1.5. Breast Cancer
      • 7.3.2. Global Pemetrexed Drug by: Distribution Channel (Volume)
        • 7.3.2.1. Online
        • 7.3.2.2. Offline
      • 7.3.3. Global Pemetrexed Drug by: Strength (Volume)
        • 7.3.3.1. 100 mg lyophilized powder/vial
        • 7.3.3.2. 500 mg lyophilized powder/vial
      • 7.3.4. Global Pemetrexed Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Pemetrexed Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pemetrexed Drug: by Application(USD Million)
  • Table 2. Pemetrexed Drug Pleural mesothelioma , by Region USD Million (2015-2020)
  • Table 3. Pemetrexed Drug Lung Cancer , by Region USD Million (2015-2020)
  • Table 4. Pemetrexed Drug Colorectal Cancer , by Region USD Million (2015-2020)
  • Table 5. Pemetrexed Drug Stomach Cancer , by Region USD Million (2015-2020)
  • Table 6. Pemetrexed Drug Breast Cancer , by Region USD Million (2015-2020)
  • Table 7. Pemetrexed Drug: by Distribution Channel(USD Million)
  • Table 8. Pemetrexed Drug Online , by Region USD Million (2015-2020)
  • Table 9. Pemetrexed Drug Offline , by Region USD Million (2015-2020)
  • Table 10. Pemetrexed Drug: by Strength(USD Million)
  • Table 11. Pemetrexed Drug 100 mg lyophilized powder/vial , by Region USD Million (2015-2020)
  • Table 12. Pemetrexed Drug 500 mg lyophilized powder/vial , by Region USD Million (2015-2020)
  • Table 13. South America Pemetrexed Drug, by Country USD Million (2015-2020)
  • Table 14. South America Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 15. South America Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 16. South America Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 17. Brazil Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 18. Brazil Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 19. Brazil Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 20. Argentina Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 21. Argentina Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 22. Argentina Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 23. Rest of South America Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 24. Rest of South America Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 25. Rest of South America Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 26. Asia Pacific Pemetrexed Drug, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 28. Asia Pacific Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 29. Asia Pacific Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 30. China Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 31. China Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 32. China Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 33. Japan Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 34. Japan Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 35. Japan Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 36. India Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 37. India Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 38. India Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 39. South Korea Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 40. South Korea Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 41. South Korea Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 42. Taiwan Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 43. Taiwan Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 44. Taiwan Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 45. Australia Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 46. Australia Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 47. Australia Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 51. Europe Pemetrexed Drug, by Country USD Million (2015-2020)
  • Table 52. Europe Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 53. Europe Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 54. Europe Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 55. Germany Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 56. Germany Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 57. Germany Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 58. France Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 59. France Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 60. France Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 61. Italy Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 62. Italy Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 63. Italy Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 64. United Kingdom Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 65. United Kingdom Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 66. United Kingdom Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 67. Netherlands Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 68. Netherlands Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 69. Netherlands Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 70. Rest of Europe Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 71. Rest of Europe Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 72. Rest of Europe Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 73. MEA Pemetrexed Drug, by Country USD Million (2015-2020)
  • Table 74. MEA Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 75. MEA Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 76. MEA Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 77. Middle East Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 78. Middle East Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 79. Middle East Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 80. Africa Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 81. Africa Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 82. Africa Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 83. North America Pemetrexed Drug, by Country USD Million (2015-2020)
  • Table 84. North America Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 85. North America Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 86. North America Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 87. United States Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 88. United States Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 89. United States Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 90. Canada Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 91. Canada Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 92. Canada Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 93. Mexico Pemetrexed Drug, by Application USD Million (2015-2020)
  • Table 94. Mexico Pemetrexed Drug, by Distribution Channel USD Million (2015-2020)
  • Table 95. Mexico Pemetrexed Drug, by Strength USD Million (2015-2020)
  • Table 96. Pemetrexed Drug Sales: by Application(K Tons)
  • Table 97. Pemetrexed Drug Sales Pleural mesothelioma , by Region K Tons (2015-2020)
  • Table 98. Pemetrexed Drug Sales Lung Cancer , by Region K Tons (2015-2020)
  • Table 99. Pemetrexed Drug Sales Colorectal Cancer , by Region K Tons (2015-2020)
  • Table 100. Pemetrexed Drug Sales Stomach Cancer , by Region K Tons (2015-2020)
  • Table 101. Pemetrexed Drug Sales Breast Cancer , by Region K Tons (2015-2020)
  • Table 102. Pemetrexed Drug Sales: by Distribution Channel(K Tons)
  • Table 103. Pemetrexed Drug Sales Online , by Region K Tons (2015-2020)
  • Table 104. Pemetrexed Drug Sales Offline , by Region K Tons (2015-2020)
  • Table 105. Pemetrexed Drug Sales: by Strength(K Tons)
  • Table 106. Pemetrexed Drug Sales 100 mg lyophilized powder/vial , by Region K Tons (2015-2020)
  • Table 107. Pemetrexed Drug Sales 500 mg lyophilized powder/vial , by Region K Tons (2015-2020)
  • Table 108. South America Pemetrexed Drug Sales, by Country K Tons (2015-2020)
  • Table 109. South America Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 110. South America Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 111. South America Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 112. Brazil Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 113. Brazil Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 114. Brazil Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 115. Argentina Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 116. Argentina Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 117. Argentina Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 118. Rest of South America Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 119. Rest of South America Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 120. Rest of South America Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 121. Asia Pacific Pemetrexed Drug Sales, by Country K Tons (2015-2020)
  • Table 122. Asia Pacific Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 123. Asia Pacific Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 124. Asia Pacific Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 125. China Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 126. China Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 127. China Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 128. Japan Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 129. Japan Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 130. Japan Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 131. India Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 132. India Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 133. India Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 134. South Korea Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 135. South Korea Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 136. South Korea Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 137. Taiwan Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 138. Taiwan Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 139. Taiwan Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 140. Australia Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 141. Australia Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 142. Australia Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 143. Rest of Asia-Pacific Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 144. Rest of Asia-Pacific Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 145. Rest of Asia-Pacific Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 146. Europe Pemetrexed Drug Sales, by Country K Tons (2015-2020)
  • Table 147. Europe Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 148. Europe Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 149. Europe Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 150. Germany Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 151. Germany Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 152. Germany Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 153. France Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 154. France Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 155. France Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 156. Italy Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 157. Italy Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 158. Italy Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 159. United Kingdom Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 160. United Kingdom Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 161. United Kingdom Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 162. Netherlands Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 163. Netherlands Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 164. Netherlands Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 165. Rest of Europe Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 166. Rest of Europe Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 167. Rest of Europe Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 168. MEA Pemetrexed Drug Sales, by Country K Tons (2015-2020)
  • Table 169. MEA Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 170. MEA Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 171. MEA Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 172. Middle East Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 173. Middle East Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 174. Middle East Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 175. Africa Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 176. Africa Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 177. Africa Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 178. North America Pemetrexed Drug Sales, by Country K Tons (2015-2020)
  • Table 179. North America Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 180. North America Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 181. North America Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 182. United States Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 183. United States Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 184. United States Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 185. Canada Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 186. Canada Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 187. Canada Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 188. Mexico Pemetrexed Drug Sales, by Application K Tons (2015-2020)
  • Table 189. Mexico Pemetrexed Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 190. Mexico Pemetrexed Drug Sales, by Strength K Tons (2015-2020)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Pemetrexed Drug: by Application(USD Million)
  • Table 202. Pemetrexed Drug Pleural mesothelioma , by Region USD Million (2021-2026)
  • Table 203. Pemetrexed Drug Lung Cancer , by Region USD Million (2021-2026)
  • Table 204. Pemetrexed Drug Colorectal Cancer , by Region USD Million (2021-2026)
  • Table 205. Pemetrexed Drug Stomach Cancer , by Region USD Million (2021-2026)
  • Table 206. Pemetrexed Drug Breast Cancer , by Region USD Million (2021-2026)
  • Table 207. Pemetrexed Drug: by Distribution Channel(USD Million)
  • Table 208. Pemetrexed Drug Online , by Region USD Million (2021-2026)
  • Table 209. Pemetrexed Drug Offline , by Region USD Million (2021-2026)
  • Table 210. Pemetrexed Drug: by Strength(USD Million)
  • Table 211. Pemetrexed Drug 100 mg lyophilized powder/vial , by Region USD Million (2021-2026)
  • Table 212. Pemetrexed Drug 500 mg lyophilized powder/vial , by Region USD Million (2021-2026)
  • Table 213. South America Pemetrexed Drug, by Country USD Million (2021-2026)
  • Table 214. South America Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 215. South America Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 216. South America Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 217. Brazil Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 218. Brazil Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 219. Brazil Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 220. Argentina Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 221. Argentina Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 222. Argentina Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 223. Rest of South America Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 224. Rest of South America Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 225. Rest of South America Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 226. Asia Pacific Pemetrexed Drug, by Country USD Million (2021-2026)
  • Table 227. Asia Pacific Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 228. Asia Pacific Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 229. Asia Pacific Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 230. China Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 231. China Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 232. China Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 233. Japan Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 234. Japan Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 235. Japan Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 236. India Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 237. India Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 238. India Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 239. South Korea Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 240. South Korea Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 241. South Korea Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 242. Taiwan Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 243. Taiwan Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 244. Taiwan Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 245. Australia Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 246. Australia Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 247. Australia Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 249. Rest of Asia-Pacific Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 250. Rest of Asia-Pacific Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 251. Europe Pemetrexed Drug, by Country USD Million (2021-2026)
  • Table 252. Europe Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 253. Europe Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 254. Europe Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 255. Germany Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 256. Germany Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 257. Germany Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 258. France Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 259. France Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 260. France Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 261. Italy Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 262. Italy Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 263. Italy Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 264. United Kingdom Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 265. United Kingdom Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 266. United Kingdom Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 267. Netherlands Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 268. Netherlands Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 269. Netherlands Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 270. Rest of Europe Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 271. Rest of Europe Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 272. Rest of Europe Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 273. MEA Pemetrexed Drug, by Country USD Million (2021-2026)
  • Table 274. MEA Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 275. MEA Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 276. MEA Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 277. Middle East Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 278. Middle East Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 279. Middle East Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 280. Africa Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 281. Africa Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 282. Africa Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 283. North America Pemetrexed Drug, by Country USD Million (2021-2026)
  • Table 284. North America Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 285. North America Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 286. North America Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 287. United States Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 288. United States Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 289. United States Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 290. Canada Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 291. Canada Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 292. Canada Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 293. Mexico Pemetrexed Drug, by Application USD Million (2021-2026)
  • Table 294. Mexico Pemetrexed Drug, by Distribution Channel USD Million (2021-2026)
  • Table 295. Mexico Pemetrexed Drug, by Strength USD Million (2021-2026)
  • Table 296. Pemetrexed Drug Sales: by Application(K Tons)
  • Table 297. Pemetrexed Drug Sales Pleural mesothelioma , by Region K Tons (2021-2026)
  • Table 298. Pemetrexed Drug Sales Lung Cancer , by Region K Tons (2021-2026)
  • Table 299. Pemetrexed Drug Sales Colorectal Cancer , by Region K Tons (2021-2026)
  • Table 300. Pemetrexed Drug Sales Stomach Cancer , by Region K Tons (2021-2026)
  • Table 301. Pemetrexed Drug Sales Breast Cancer , by Region K Tons (2021-2026)
  • Table 302. Pemetrexed Drug Sales: by Distribution Channel(K Tons)
  • Table 303. Pemetrexed Drug Sales Online , by Region K Tons (2021-2026)
  • Table 304. Pemetrexed Drug Sales Offline , by Region K Tons (2021-2026)
  • Table 305. Pemetrexed Drug Sales: by Strength(K Tons)
  • Table 306. Pemetrexed Drug Sales 100 mg lyophilized powder/vial , by Region K Tons (2021-2026)
  • Table 307. Pemetrexed Drug Sales 500 mg lyophilized powder/vial , by Region K Tons (2021-2026)
  • Table 308. South America Pemetrexed Drug Sales, by Country K Tons (2021-2026)
  • Table 309. South America Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 310. South America Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 311. South America Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 312. Brazil Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 313. Brazil Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 314. Brazil Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 315. Argentina Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 316. Argentina Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 317. Argentina Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 318. Rest of South America Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 319. Rest of South America Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 320. Rest of South America Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 321. Asia Pacific Pemetrexed Drug Sales, by Country K Tons (2021-2026)
  • Table 322. Asia Pacific Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 323. Asia Pacific Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 324. Asia Pacific Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 325. China Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 326. China Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 327. China Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 328. Japan Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 329. Japan Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 330. Japan Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 331. India Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 332. India Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 333. India Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 334. South Korea Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 335. South Korea Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 336. South Korea Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 337. Taiwan Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 338. Taiwan Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 339. Taiwan Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 340. Australia Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 341. Australia Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 342. Australia Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 343. Rest of Asia-Pacific Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 344. Rest of Asia-Pacific Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 345. Rest of Asia-Pacific Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 346. Europe Pemetrexed Drug Sales, by Country K Tons (2021-2026)
  • Table 347. Europe Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 348. Europe Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 349. Europe Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 350. Germany Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 351. Germany Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 352. Germany Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 353. France Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 354. France Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 355. France Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 356. Italy Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 357. Italy Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 358. Italy Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 359. United Kingdom Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 360. United Kingdom Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 361. United Kingdom Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 362. Netherlands Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 363. Netherlands Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 364. Netherlands Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 365. Rest of Europe Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 366. Rest of Europe Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 367. Rest of Europe Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 368. MEA Pemetrexed Drug Sales, by Country K Tons (2021-2026)
  • Table 369. MEA Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 370. MEA Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 371. MEA Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 372. Middle East Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 373. Middle East Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 374. Middle East Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 375. Africa Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 376. Africa Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 377. Africa Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 378. North America Pemetrexed Drug Sales, by Country K Tons (2021-2026)
  • Table 379. North America Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 380. North America Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 381. North America Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 382. United States Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 383. United States Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 384. United States Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 385. Canada Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 386. Canada Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 387. Canada Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 388. Mexico Pemetrexed Drug Sales, by Application K Tons (2021-2026)
  • Table 389. Mexico Pemetrexed Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 390. Mexico Pemetrexed Drug Sales, by Strength K Tons (2021-2026)
  • Table 391. Research Programs/Design for This Report
  • Table 392. Key Data Information from Secondary Sources
  • Table 393. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pemetrexed Drug: by Application USD Million (2015-2020)
  • Figure 5. Global Pemetrexed Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Pemetrexed Drug: by Strength USD Million (2015-2020)
  • Figure 7. South America Pemetrexed Drug Share (%), by Country
  • Figure 8. Asia Pacific Pemetrexed Drug Share (%), by Country
  • Figure 9. Europe Pemetrexed Drug Share (%), by Country
  • Figure 10. MEA Pemetrexed Drug Share (%), by Country
  • Figure 11. North America Pemetrexed Drug Share (%), by Country
  • Figure 12. Global Pemetrexed Drug: by Application K Tons (2015-2020)
  • Figure 13. Global Pemetrexed Drug: by Distribution Channel K Tons (2015-2020)
  • Figure 14. Global Pemetrexed Drug: by Strength K Tons (2015-2020)
  • Figure 15. South America Pemetrexed Drug Share (%), by Country
  • Figure 16. Asia Pacific Pemetrexed Drug Share (%), by Country
  • Figure 17. Europe Pemetrexed Drug Share (%), by Country
  • Figure 18. MEA Pemetrexed Drug Share (%), by Country
  • Figure 19. North America Pemetrexed Drug Share (%), by Country
  • Figure 20. Global Pemetrexed Drug share by Players 2020 (%)
  • Figure 21. Global Pemetrexed Drug share by Players (Top 3) 2020(%)
  • Figure 22. Global Pemetrexed Drug share by Players (Top 5) 2020(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 25. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 26. Fresenius KABI (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Fresenius KABI (Germany) Revenue: by Geography 2020
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 30. Dr Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 31. Dr Reddy’s Laboratories (India) Revenue: by Geography 2020
  • Figure 32. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 33. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 34. Cadila Healthcare Ltd (India) Revenue, Net Income and Gross profit
  • Figure 35. Cadila Healthcare Ltd (India) Revenue: by Geography 2020
  • Figure 36. Accord Healthcare Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Accord Healthcare Inc. (United States) Revenue: by Geography 2020
  • Figure 38. QILU Pharma Co Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 39. QILU Pharma Co Ltd. (China) Revenue: by Geography 2020
  • Figure 40. Accure Labs Pvt. Ltd (India) Revenue, Net Income and Gross profit
  • Figure 41. Accure Labs Pvt. Ltd (India) Revenue: by Geography 2020
  • Figure 42. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 44. Global Pemetrexed Drug: by Application USD Million (2021-2026)
  • Figure 45. Global Pemetrexed Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 46. Global Pemetrexed Drug: by Strength USD Million (2021-2026)
  • Figure 47. South America Pemetrexed Drug Share (%), by Country
  • Figure 48. Asia Pacific Pemetrexed Drug Share (%), by Country
  • Figure 49. Europe Pemetrexed Drug Share (%), by Country
  • Figure 50. MEA Pemetrexed Drug Share (%), by Country
  • Figure 51. North America Pemetrexed Drug Share (%), by Country
  • Figure 52. Global Pemetrexed Drug: by Application K Tons (2021-2026)
  • Figure 53. Global Pemetrexed Drug: by Distribution Channel K Tons (2021-2026)
  • Figure 54. Global Pemetrexed Drug: by Strength K Tons (2021-2026)
  • Figure 55. South America Pemetrexed Drug Share (%), by Country
  • Figure 56. Asia Pacific Pemetrexed Drug Share (%), by Country
  • Figure 57. Europe Pemetrexed Drug Share (%), by Country
  • Figure 58. MEA Pemetrexed Drug Share (%), by Country
  • Figure 59. North America Pemetrexed Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Eli Lilly and Company (United States)
  • Fresenius KABI (Germany)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Dr Reddy’s Laboratories (India)
  • Abbott Laboratories (United States)
  • Cadila Healthcare Ltd (India)
  • Accord Healthcare Inc. (United States)
  • QILU Pharma Co Ltd. (China)
  • Accure Labs Pvt. Ltd (India)
  • Pfizer Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 210 Pages 53 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pemetrexed Drug Market Quantitative research analysis
Global Pemetrexed Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Use of Chemotherapy Drugs in Developing Countries " is seen as one of major growth factors of Pemetrexed Drug Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Pemetrexed Drug Market Report?

Have a Query? Click Here

Other Related Reports

Trazodone Hydrochloride Comprehensive Study by Type (Tablet, Capsule), Application (Antidepression, Anxiolytic, Hypnotic, Others), (), Depression (Major Depression, Bipolar Disorder, Psychotic Depr...
$ 3650
Pain Management Drugs Comprehensive Study by Type (Generic Opioids, Branded Opioids), Application (Burn Pain, Cancer Pain, Dental/Facial Pain, Migraine Headache Pain, Musculoskeletal Pain, Neuropathi...
$ 3750
Acromegaly and Gigantism Drugs Comprehensive Study by Type (Somatostatin Analogs, GH Receptor Antagonists, Dopamine Agonists, Recombinant Human IGF-1), Distribution Channel (Retail Pharmacies, Hospit...
$ 3350
DPT Vaccines Comprehensive Study by Type (DPaT, DTwP, Tdap), Application (Diphtheria, Tetanus, Pertussis, Others), Vaccine Type (Whole-Cell Vaccine, Acellular Vaccine), End-User (Adult, Pediatric) Pl...
$ 3500
Pharmaceutical Hot Melt Extrusion Comprehensive Study by Type (Single Screw Extruder, Twin Screw Extruder, Laboratory Extruder, RAM Extruder), End User (Research Laboratory, Contract Manufacturing Or...
$ 3350
Necrotizing Fasciitis Comprehensive Study by Application (Hospital & Clinics, Surgical Centers), Treatment (Surgical debridement, Antibiotics, Amputation), Diagnosis (Clinical examination, Blood and ...
$ 3800